Introduction: Drug-Induced PAH Is Rare—Until It Is Not
Pulmonary arterial hypertension (PAH) is often taught as a disease of idiopathic mutations, connective tissue disorders, or congenital heart disease. In daily practice, however, clinicians increasingly encounter PAH as an iatrogenic condition, emerging quietly after long exposure to drugs that were prescribed for entirely different—and often life-threatening—reasons. Drug-associated PAH remains uncommon, but its rarity is deceptive: once it develops, it behaves like classic PAH, with progressive vascular remodeling, right ventricular strain, and high morbidity.
Cyclophosphamide is a prime example of this paradox. It is a cornerstone alkylating agent used for decades in hematologic malignancies, autoimmune diseases, and transplant protocols. Its toxicities are well known—myelosuppression, hemorrhagic cystitis, infertility, secondary malignancies. Pulmonary arterial hypertension, however, remains an underrecognized late complication, especially when cyclophosphamide is administered chronically at relatively low doses.
The case of an 80-year-old man who developed right-heart-catheterization-confirmed PAH after seven years of cyclophosphamide monotherapy forces clinicians to confront an uncomfortable truth: even “stable,” long-term chemotherapy can silently reshape pulmonary vasculature. This case is particularly instructive because alternative explanations were rigorously excluded, and the hemodynamic course was carefully documented before and after treatment intervention.
This article uses that case as a framework to explore how cyclophosphamide can induce PAH, why diagnosis is often delayed, how to distinguish it from pulmonary veno-occlusive disease (PVOD), and what practical lessons clinicians should apply when managing patients receiving long-term alkylating agents.
Cyclophosphamide: A Drug With Two Faces
Cyclophosphamide is valued for its broad immunosuppressive and cytotoxic activity. By cross-linking DNA, it halts proliferation of malignant and autoreactive cells. In diseases such as primary macroglobulinemia, it may provide long-term disease control with acceptable tolerability—especially in elderly patients for whom more aggressive regimens are unsuitable.
Yet cyclophosphamide is not biologically selective. Its metabolites circulate systemically and interact with endothelial cells, smooth muscle cells, and immune mediators. While acute cardiotoxicity at high doses is well described, chronic low-dose exposure produces a subtler pattern of injury—one that may unfold over years and preferentially affect microvascular beds, including the pulmonary circulation.
Importantly, most patients receiving cyclophosphamide do not develop PAH. This suggests that susceptibility depends on cumulative exposure, genetic factors, endothelial reserve, age, and comorbid conditions. The problem is that when PAH does develop, it often does so after years of uneventful treatment, at a point when clinicians are least vigilant.
The presented case exemplifies this delayed toxicity. The patient tolerated cyclophosphamide for seven years without cardiopulmonary abnormalities. A transthoracic echocardiogram three years prior to symptom onset was normal. Only after progressive exertional dyspnea developed did pulmonary hypertension enter the differential.
Clinical Presentation: When Dyspnea Refuses to Be Explained Away
The patient’s initial symptom—progressive dyspnea on exertion—is among the least specific in medicine. In an 80-year-old man with anemia, prior chemotherapy, and a hematologic malignancy, dyspnea can be easily attributed to deconditioning, age, or cardiopulmonary comorbidity. This is precisely why drug-induced PAH is often diagnosed late.
Despite discontinuation of cyclophosphamide, the patient’s symptoms failed to improve. This is a critical point: stopping the offending agent does not guarantee rapid reversal. By the time symptoms manifest, vascular remodeling may already be established. This distinguishes late-onset PAH from early, high-dose cyclophosphamide toxicity, where vasoconstriction and endothelial dysfunction may be partially reversible.
Diagnostic evaluation revealed a classic PAH phenotype. Right heart catheterization showed precapillary pulmonary hypertension with a markedly elevated mean pulmonary artery pressure (48 mmHg initially), normal pulmonary artery wedge pressure, and increased pulmonary vascular resistance. Importantly, imaging excluded chronic thromboembolic disease, lung parenchymal pathology, and left-sided heart disease. Genetic testing for heritable PAH was negative.
In short, the patient had PAH—and cyclophosphamide exposure was the only identifiable risk factor.
The DLCO Clue and the Shadow of PVOD
One of the most striking findings in this case was the severely reduced diffusing capacity for carbon monoxide (DLCO)—approximately 11% of predicted. In PAH, DLCO may be mildly to moderately reduced, but values this low raise immediate concern for pulmonary veno-occlusive disease (PVOD).
PVOD is a rare but devastating cause of pulmonary hypertension characterized by fibrotic obstruction of small pulmonary veins. It is notorious for masquerading as PAH while responding poorly—or dangerously—to standard vasodilator therapy. Cyclophosphamide is among the drugs most frequently implicated in PVOD development.
The authors carefully evaluated this possibility. High-resolution CT imaging showed no interlobular septal thickening, centrilobular ground-glass opacities, or mediastinal lymphadenopathy—hallmarks of PVOD. Ventilation-perfusion scanning was normal. Importantly, cautious initiation of tadalafil did not precipitate pulmonary edema, which would be expected in overt PVOD.
Nevertheless, the authors appropriately acknowledge diagnostic uncertainty. PVOD and PAH likely exist on a spectrum of cyclophosphamide-induced pulmonary vasculopathy. The profoundly low DLCO suggests that venous involvement may have been present, even if not radiographically overt.
Pathophysiology: How Cyclophosphamide Remodels the Pulmonary Vasculature
Animal and human data suggest that cyclophosphamide damages pulmonary vessels through multiple converging mechanisms. Experimental models demonstrate medial hypertrophy of pulmonary arteries, neomuscularization of distal arterioles, thickening of pulmonary veins, and fibrotic remodeling of alveolar septa. Endothelial dysfunction appears central, with increased endothelin-1 expression promoting vasoconstriction and smooth muscle proliferation.
Importantly, the pattern of injury differs by dose and duration. High-dose, short-term exposure may produce reversible vasoconstriction and inflammatory injury. In contrast, low-dose, long-term exposure, as in this case, is more likely to cause irreversible structural remodeling—fibrosis rather than spasm.
This distinction explains the patient’s incomplete recovery despite drug discontinuation. It also parallels known pulmonary toxicities of cyclophosphamide, where early lung injury may resolve, but late-onset disease leads to permanent fibrosis. The pulmonary vasculature appears to follow a similar rule.
Another intriguing aspect is age. Endothelial repair capacity declines with age, potentially making elderly patients more vulnerable to cumulative toxic insults. In this sense, the patient’s age may have been as important as the drug itself.
Treatment Strategy: Caution, Precision, and Measured Optimism
Management of suspected cyclophosphamide-associated PAH begins with immediate discontinuation of the drug. This is necessary but rarely sufficient. Once PAH is established, targeted pulmonary vasodilator therapy should be considered—carefully.
Given the concern for occult PVOD, the clinicians chose tadalafil monotherapy, initiated at low dose and titrated upward. This cautious approach reflects an important clinical principle: in drug-induced PAH with possible venous involvement, aggressive combination therapy may provoke pulmonary edema.
The patient responded favorably. Over two months, dyspnea improved and repeat right heart catheterization showed meaningful hemodynamic improvement: reduced mean pulmonary artery pressure, lower pulmonary vascular resistance, and improved cardiac output. Brain natriuretic peptide levels also declined.
This response confirms that even in late-onset cyclophosphamide-associated PAH, functional improvement is possible. However, the persistence of elevated pulmonary vascular resistance suggests partial reversibility at best. This reinforces the importance of early recognition—before fibrosis becomes dominant.
Clinical Implications: What Practicing Physicians Should Learn
This case carries lessons far beyond its rarity. Cyclophosphamide is widely prescribed, often for years, and often by clinicians who may not routinely screen for pulmonary hypertension. Dyspnea in these patients should never be dismissed.
Baseline and periodic echocardiography may be reasonable in patients receiving long-term cyclophosphamide, especially elderly individuals or those with cumulative exposure. A declining DLCO, even in the absence of radiographic lung disease, should prompt serious consideration of pulmonary vascular pathology.
Equally important is diagnostic rigor. Drug-induced PAH remains a diagnosis of exclusion. This case stands out because right heart catheterization was performed, alternative causes were systematically ruled out, and serial hemodynamic data were documented. Without that rigor, cyclophosphamide-associated PAH remains invisible—or worse, misclassified.
Finally, this case reminds clinicians that stopping a drug does not erase its legacy. Vascular remodeling, once established, behaves autonomously. Treatment goals should therefore focus on stabilization, symptom improvement, and preservation of right ventricular function rather than cure.
Conclusion: Recognizing the Quiet Toxicity
Cyclophosphamide has saved countless lives. Yet, as this case illustrates, it can also leave a delayed vascular footprint that emerges long after initial therapeutic success. Pulmonary arterial hypertension after long-term cyclophosphamide use is rare, insidious, and potentially irreversible, but not untreatable.
The presented case demonstrates that careful diagnostic evaluation, early recognition, and judicious use of pulmonary vasodilators can meaningfully improve patient outcomes—even in advanced age. It also highlights the need for heightened vigilance among clinicians prescribing long-term alkylating agents.
In modern medicine, survival is no longer the only endpoint. Long-term toxicity matters. Cyclophosphamide-associated PAH is a reminder that when patients live longer, we must think longer as well.
FAQ
1. How common is pulmonary arterial hypertension caused by cyclophosphamide?
It is very rare, with only a small number of well-documented cases, but it is likely underdiagnosed due to delayed onset and nonspecific symptoms.
2. Can cyclophosphamide-associated PAH reverse after stopping the drug?
Early cases may improve, especially after high-dose short-term exposure. Long-term low-dose exposure, as in this case, often leads to partial or irreversible vascular remodeling.
3. Why was tadalafil chosen instead of combination PAH therapy?
Because of concern for possible pulmonary veno-occlusive disease, where aggressive vasodilation can cause pulmonary edema. Low-dose PDE5 inhibition offers a safer initial strategy.
